Welcome to LookChem.com Sign In|Join Free

CAS

  • or

583840-03-3

Post Buying Request

583840-03-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

583840-03-3 Usage

Chemical Properties

Pale Yellow Solid

Uses

A metabolite of Sorafenib, a potent Raf kinase inhibitor.

Check Digit Verification of cas no

The CAS Registry Mumber 583840-03-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,8,3,8,4 and 0 respectively; the second part has 2 digits, 0 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 583840-03:
(8*5)+(7*8)+(6*3)+(5*8)+(4*4)+(3*0)+(2*0)+(1*3)=173
173 % 10 = 3
So 583840-03-3 is a valid CAS Registry Number.
InChI:InChI=1/C21H16ClF3N4O4/c1-26-19(30)18-11-15(8-9-29(18)32)33-14-5-2-12(3-6-14)27-20(31)28-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,27,28,31)

583840-03-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name Sorafenib N-Oxide

1.2 Other means of identification

Product number -
Other names 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-1-oxidopyridin-1-ium-2-carboxamide

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:583840-03-3 SDS

583840-03-3Upstream product

583840-03-3Downstream Products

583840-03-3Relevant articles and documents

Aryl ureas as kinase inhibitors

-

Page/Page column 21, (2015/11/30)

This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VE

Aryl ureas as kinase inhibitors

-

, (2008/06/13)

This invention relates to new aryl ureas and methods for their synthesis. The inventive compounds are useful in the treatment of (i) raf mediated diseases, for example, cancer, (ii) p38 mediated diseases such as inflammation and osteoporosis, and (iii) VEGF mediated diseases such as angiogenesis disorders.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 583840-03-3